Clinical trials should be advanced in phases: phase I focuses on evaluating toxicity and pharmacokinetics; phase II explores the synergistic effect of combination therapies (e.g., with selonsertib or IL-22) on severe alcoholic hepatitis, and detects novel biomarkers, such as serum sC5b9 and intestinal barrier markers (e.g., claudin-3, LBP); and phase III verifies the benefits of long-term intervention on fibrosis reversal and hepatocellular carcinoma prevention. This evidence concerns the gene CLDN3 and hepatocellular carcinoma.